LARKSPUR, Calif. and STAMFORD, Conn. — The Global Coalition for Adaptive Research (GCAR) and Purdue Pharma L.P. (Purdue) today announced the activation of investigational tinostamustine in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment – NCT03970447), a pioneering, international adaptive platform trial designed to accelerate the identification of effective treatments for...

NATICK, Mass. — AllRock Bio, Inc., a clinical-stage biotechnology company focused on advancing impactful therapies for cardiopulmonary and fibrotic diseases, today announced the dosing of the first patients in the Phase 2a ROCSTAR trial of ROC-101, a first-in-class, oral pan-rho-associated protein kinase (ROCK) inhibitor, in pulmonary hypertension (PH). Building on Phase 1...

CAMBRIDGE, Mass. — Anumana, Inc., a leader in cardiovascular AI, today announced U.S. Food and Drug Administration (FDA) clearance of its ECG-AI™ algorithm for cardiac amyloidosis (CA) – the first and only cleared for this indication using standard 12-lead electrocardiograms (ECGs). The AI-enabled software-as-a-medical-device (SaMD), previously granted FDA Breakthrough Device Designation and...